Health Care

Phio Pharmaceuticals advances cancer immunotherapy, tackling R&D and market volatility while targeting personalized treatments—discover its biotech prospects.

Ocugen’s recent Form 144 filing details the insider sale of 400k+ shares, highlighting its biotech focus and stock movement for investors.

Fate Therapeutics, a San Diego biotech, pioneers stem‑cell therapies for tissue repair, driving regenerative medicine breakthroughs and offering new hope for patients.

Arcturus Therapeutics’ RNA‑therapy ambitions clash with sharp stock swings, a negative P/E, and complex Federated Hermes ownership, raising investor concerns.

Discover how Corcept Therapeutics’ cortisol‑modulating drug targets GR‑II to treat metabolic and psychiatric disorders, driving strong stock growth and future healthcare innovation.

Explore how Hyperliquid Strategies, Inc. navigated the 2026 crypto crash, leveraged positions, and regulatory shifts to stay resilient in the volatile market.

Discover EMEIS SA’s latest stock snapshot: 1.6B EUR market cap, 52‑week highs/lows, and a negative P/E—key insights for investors in France’s elder care sector.

VentriPoint Diagnostics transforms existing imaging into 3‑D heart models, boosting diagnostic accuracy and patient outcomes. Discover their cutting‑edge tech and market potential.

CRISPR Therapeutics AG faces a pivotal AHA presentation that could unlock its gene‑editing breakthrough in cardiovascular care, offering investors a high‑potential but volatile opportunity.

Johnson & Johnson’s two‑year ICOTYDE data show sustained plaque psoriasis clearance, strong safety and investor optimism, signaling a promising future for the biologic.